Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Efficacy and Safety of JS002 in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia in China

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Efficacy and Safety of JS002 in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia in China

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ongericimab (Primary) ; HMG-CoA reductase inhibitors
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Junshi Biosciences

    • Most Recent Events

    • 11 Oct 2024 According to Shanghai Junshi Biosciences media release, this study is led by Academician Yaling HAN from the General Hospital of the Northern Theater Command of the People's Liberation Army of China.
    • 11 Oct 2024 According to Shanghai Junshi Biosciences media release, National Medical Products Administration (NMPA) has approved new drug applications (NDA) for ongericimab injection for the treatment of primary hypercholesterolemia and mixed dyslipidemia, based on results from this study.
    • 25 Apr 2023 According to a Junshi Biosciences - Impact Therapeutics (JV) media release, the National Medical Products Administration has accepted the new drug application for JS002. new drug application is mainly based on three registered clinical trials (JS002-003, JS002-004 and JS002-006).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top